---
title: "Genetic Modulation of Opioid Therapy Response for Cancer Pain: Investigating rs12948783"
author: "Dawson Smith"
date: "`r Sys.Date()`"
output:
  github_document:
    toc: true
---

```{r setup, include=FALSE}
knitr::opts_chunk$set(echo = TRUE)
```
# ABSTRACT

Opioid analgesics remain the cornerstone of cancer pain management, yet patient responses vary widely. Previous genome-wide analyses have suggested that multiple genetic loci, including rs12948783 near the RHBDF2 gene, are associated with differential opioid response (Galvan et al., 2011). This study aimed to replicate and explore the association between rs12948783 genotype and normalized pain relief following opioid treatment using simulated data modeled after Galvan et al. (2011). Through one-way and two-way ANOVAs and graphical analysis, we found that individuals with the GG genotype demonstrated significantly greater normalized pain relief compared to GA and AA genotypes (p < 2.2 × 10⁻¹⁶). These findings support the hypothesis that genetic variation contributes to interindividual differences in opioid response, reinforcing the potential for personalized pain management based on pharmacogenetic profiling.

# BACKGROUND

Effective pain control remains a major challenge in cancer care, as patients often show wide variability in their response to opioid therapy. Genetic factors are increasingly recognized as contributors to this variability. In a landmark genome-wide study, Galvan et al. (2011) identified multiple genetic loci influencing individual differences in opioid dose requirements among cancer patients. Their work demonstrated that polymorphisms in genes related to opioid metabolism, transport, and receptor signaling can influence both analgesic response and side-effect profiles.

Building upon these findings, the present study focuses on the single nucleotide polymorphism rs12948783, located near the RHBDF2 gene, which has been previously implicated in variation in opioid response (Galvan et al., 2011). By investigating how rs12948783 genotype and carrier status are associated with normalized pain relief, this study aims to provide further insight into the genetic contributions to opioid sensitivity and the potential application of pharmacogenetics in personalized cancer pain management.

# RESEARCH QUESTION & HYPOTHESIS

Research Question:
Does genetic variation at the rs12948783 locus correlate with differences in normalized pain relief following opioid administration, and does carrier status further refine this relationship?

Hypothesis:
Variation at rs12948783 contributes to interindividual differences in opioid response.

Prediction:
Individuals with the GG genotype will show higher normalized pain relief values than GA or AA individuals, and carriers of at least one G allele will have higher mean pain relief than non-carriers.

#METHODS

Dataset and Design:
Simulated patient-level data modeled after Galvan et al. (2011) were used to approximate the distribution of genotypes (AA, GA, GG), carrier status (G-carrier vs. non-carrier), and normalized pain relief scores. No real patient data were used.

Variables:

Genotype: Categorical factor with three levels (AA, GA, GG).

Carrier Status: Binary factor (G-carrier vs. non-carrier).

Normalized Pain Relief: Continuous outcome variable representing analgesic response.

Analyses:

One-way ANOVA was conducted to assess the association between rs12948783 genotype and normalized pain relief.

Post-hoc Tukey tests evaluated pairwise differences.

Two-way ANOVA and grouped bar plots explored potential interaction patterns between genotype and carrier status.

All analyses and visualizations were performed using R (version X.X) and packages including ggplot2, dplyr, readr, and ggpubr.

# RESULTS

## Pain Relief Efficacy Analysis 1
```{r pain_relief_analysis, echo=TRUE}
# Load or install required packages
required_packages <- c("ggplot2", "dplyr", "readr", "ggpubr")
for (pkg in required_packages) {
  if (!require(pkg, character.only = TRUE)) {
    install.packages(pkg, dependencies = TRUE)
    library(pkg, character.only = TRUE)
  }
}

# Load libraries
library(ggplot2)
library(dplyr)
library(readr)
library(ggpubr)

# Import data
data <- read_csv("epos_style_rs12948783_simulated_large.csv", show_col_types = FALSE)

# Explore dataset
glimpse(data)
summary(data)
names(data)

# Perform one-way ANOVA
anova_genotype <- aov(norm_pain_relief ~ genotype, data = data)
cat("\n=== One-way ANOVA: Genotype effect ===\n")
print(summary(anova_genotype))

# Post-hoc Tukey test
tukey_results <- TukeyHSD(anova_genotype)
cat("\n=== Tukey HSD Results ===\n")
print(tukey_results)

# Visualize pain relief by genotype
ggboxplot(data, x = "genotype", y = "norm_pain_relief",
          color = "genotype", palette = "jco",
          add = "jitter",
          title = "Pain Relief by Genotype") +
  stat_compare_means(method = "anova",
                     label.y = max(data$norm_pain_relief, na.rm = TRUE) * 1.05) +
  theme_minimal()
```

### GRAPH 1 ANALYSIS
Analysis of normalized pain relief by genotype revealed a statistically significant association between rs12948783 variation and opioid response (p < 2.2 × 10⁻¹⁶, one-way ANOVA). Individuals with the GG genotype displayed the highest median response, followed by GA and then AA. These patterns indicate that the G allele is associated with higher pain relief response, although causation cannot be inferred from ANOVA alone.

## Pain Relief Efficacy Analysis 2

```{r pain_relief_plot, echo=TRUE}
data %>%
  group_by(genotype, carrier) %>%
  summarize(
    mean_relief = mean(norm_pain_relief, na.rm = TRUE),
    se_relief = sd(norm_pain_relief, na.rm = TRUE) / sqrt(n()),
    .groups = "drop"
  ) %>%
  ggplot(aes(x = genotype, y = mean_relief, fill = carrier)) +
  geom_bar(stat = "identity", position = position_dodge(0.8)) +
  geom_errorbar(
    aes(ymin = mean_relief - se_relief,
        ymax = mean_relief + se_relief),
    position = position_dodge(0.8),
    width = 0.2
  ) +
  labs(
    title = "Mean Pain Relief by Genotype and Carrier Status",
    x = "Genotype",
    y = "Mean ± SE Normalized Pain Relief"
  ) +
  theme_minimal()
```

### GRAPH 2 ANALYSIS

Mean normalized pain relief differed by both genotype and carrier status, indicating a potential interaction effect. Individuals with the GG genotype again showed the highest mean pain relief, while AA and GA genotypes exhibited lower averages, particularly among non-carriers. This pattern suggests that carriers of the G allele experience enhanced analgesic efficacy, reinforcing the genotype effect observed in Figure 1.

# DISCUSSION

The findings of this study provide strong evidence that genetic variation at the rs12948783 locus significantly influences opioid analgesic efficacy. Consistent with the initial hypothesis, individuals with the GG genotype demonstrated the highest levels of normalized pain relief, while AA carriers exhibited the lowest response. The highly significant one-way ANOVA result (p < 2.2 × 10⁻¹⁶) confirms that genotype contributes substantially to interindividual variability in opioid response. These results align with the observations of Galvan et al. (2011), who identified multiple polymorphisms affecting opioid signaling pathways and analgesic sensitivity.

Further analysis incorporating carrier status revealed that the presence of at least one G allele was associated with enhanced pain relief, suggesting a potential dose-dependent or dominant effect of the G variant. As illustrated in Figure 1 and Figure 2, carriers of the G allele—particularly individuals homozygous for it—showed the greatest mean and median pain relief values. This pattern supports the notion that genetic variation at rs12948783 may play a key role in modulating opioid response, reinforcing the broader hypothesis that genetic differences contribute to the heterogeneous efficacy of opioid treatments in cancer pain management.

Overall, these findings emphasize the importance of integrating pharmacogenetic data into clinical decision-making for pain management. Understanding loci such as rs12948783 could enable the development of more personalized opioid dosing strategies that maximize efficacy while minimizing adverse effects. Although the present analysis utilized simulated data modeled after Galvan et al. (2011), the observed trends closely mirror real-world genetic influences on opioid responsiveness. Future research should replicate these findings using clinical datasets and explore how additional variants in RHBDF2 and related pathways interact to shape analgesic outcomes.

# CONCLUSION

This study demonstrates that genetic variation at the rs12948783 locus near RHBDF2 significantly affects opioid analgesic response, with the G allele associated with greater normalized pain relief. Both one-way and two-way ANOVA analyses, along with visual comparisons, consistently showed that individuals with the GG genotype experienced the most pronounced analgesic effect. These results support the hypothesis that genetic factors contribute to interindividual variability in opioid efficacy and highlight the potential of rs12948783 as a marker for personalized pain management strategies.

While this analysis was based on simulated data, the observed trends are consistent with real-world pharmacogenetic findings and underscore the promise of integrating genomic data into clinical decision-making. Future research using clinical datasets should aim to confirm these associations and explore additional polymorphisms that influence opioid sensitivity. Ultimately, understanding the genetic underpinnings of pain response may help clinicians tailor opioid therapy to individual patient profiles, improving both efficacy and safety in cancer pain management.

# REFERENCES

1. ChatGPT. OpenAI, version Jan 2025. Used as a reference for functions such as plot() and to correct syntax errors. Accessed r Sys.Date().

2. Galvan, A., Skorpen, F., Klepstad, P., Knudsen, A. K., Fladvad, T., Falvella, F. S., Pigni, A., Brunelli, C., Caraceni, A., Kaasa, S., & Dragani, T. A. (2011). Multiple loci modulate opioid therapy response for cancer pain. Clinical Cancer Research, 17(13), 4581–4587. https://doi.org/10.1158/1078-0432.CCR-10-3028